Financial Services -
Asset Management - Income - NYSE - US
$ 13.03
0.463 %
$ 82.9 M
Market Cap
15.33
P/E
1. INTRINSIC VALUE
Balance Sheet
Nuveen California Select Tax-Free Income Portfolio
| Current Assets | 932 K |
| Cash & Short-Term Investments | 119 K |
| Receivables | 813 K |
| Other Current Assets | 0 |
| Non-Current Assets | 88.2 M |
| Long-Term Investments | 88.2 M |
| PP&E | 0 |
| Other Non-Current Assets | 0 |
| Current Liabilities | 297 K |
| Accounts Payable | 279 K |
| Short-Term Debt | 0 |
| Other Current Liabilities | 18.3 K |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Nuveen California Select Tax-Free Income Portfolio
| Revenue | 3.7 M |
| Cost Of Revenue | 0 |
| Gross Profit | 3.7 M |
| Operating Expenses | 1.4 M |
| Operating Income | 2.29 M |
| Other Expenses | -2.81 M |
| Net Income | 5.1 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Nuveen California Select Tax-Free Income Portfolio
| Net Income | 5.1 M |
| Depreciation & Amortization | 2.81 M |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 0 |
| Change in Working Capital | 0 |
| Others | -5.1 M |
| Free Cash Flow | 0 |
Wall Street Analysts Price Targets
Nuveen California Select Tax-Free Income Portfolio
NXC has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
0.00%
DIVIDEND YIELD
0.0455 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Nuveen California Select Tax-Free Income Portfolio
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|
7. News
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
Chimeric antigen receptor T-cell (CAR-T) cell therapy NXC-201 is a novel approach to treat relapsed/refractory AL Amyloidosis NXC-201 demonstrated compelling clinical activity, rapid and deep complete responses in frail and resistant relapsed/refractory AL Amyloidosis patients LOS ANGELES, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases, announced today the Journal of Clinical Oncology (JCO) published NXC-201 clinical results in relapsed/refractory AL Amyloidosis. The data reported on 16 enrolled patients in NEXICART-1 who had received a median 4 prior lines of therapy prior to treatment with NXC-201.
globenewswire.com
- 1 month ago
Nuveen Closed-End Funds Declare Distributions and Updates to Distribution Policies
NEW YORK--(BUSINESS WIRE)--Nuveen Closed-End Funds today announced that the Board of Trustees of the Funds has approved the regular monthly and quarterly distributions. In addition, the Board of Trustees has approved updated distribution polices described below under “Monthly & Quarterly Distributions” for The Nuveen Preferred & Income Opportunities Fund (NYSE: JPC), Nuveen Preferred and Income Term Fund (NYSE: JPI), Nuveen Variable Rate Preferred & Income Fund (NYSE: NPFD), Nuveen.
businesswire.com
- 1 year ago
Weekly Closed-End Fund Roundup: January 8, 2023
21 out of 22 CEF sectors were positive on price and 20 out of 22 sectors were positive on NAV last week. MLPs are the most discounted CEF sector.
seekingalpha.com
- 2 years ago
Weekly Closed-End Fund Roundup: VFL Tender Results (December 18, 2022)
2 out of 23 CEF sectors were positive on price and 2 out of 23 sectors were positive on NAV last week. VFL offers tender results.
seekingalpha.com
- 2 years ago
Weekly Closed-End Fund Roundup: June 21, 2020
4 out of 23 CEF sectors positive on price and 6 out of 23 sectors positive on NAV last week. MLPs lead while commodities lag. Preferreds have the highest sector
seekingalpha.com
- 4 years ago
The Reopening Killed The V-Shaped Recovery
This is a weekly series focused on analyzing the previous week’s economic data releases. The objective is to concentrate on leading indicators of economic activ
seekingalpha.com
- 4 years ago
8. Profile
Summary
Nuveen California Select Tax-Free Income Portfolio NXC
COUNTRY
US
INDUSTRY
Asset Management - Income
MARKET CAP
$ 82.9 M
Dividend Yield
0.00%
Description
Nuveen California Select Tax-Free Income Portfolio is a closed-ended fixed income mutual fund launched by Nuveen Investments Inc. The fund is co-managed by Nuveen Fund Advisors LLC and Nuveen Asset Management, LLC. It invests in the fixed income markets of California. The fund invests in the securities of companies that operate across diversified sectors. It primarily invests in municipal bonds. The fund employs fundamental analysis to create its portfolio. It benchmarks the performance of its portfolio against Barclays Capital California Municipal Bond Index and S&P California Municipal Bond Index. Nuveen California Select Tax-Free Income Portfolio was formed on June 19, 1992 and is domiciled in the United States.
Contact
333 West Wacker Drive, Chicago, IL, 60606-1220
https://www.nuveen.com/CEF/Product/Overview.aspx?FundCode=NXC&refsrc=vu_nuveen.com/nxc
IPO
Date
June 19, 1992
Employees
None
Officers